Thursday, December 8, 2022
News

Ocugen to commercialize Covaxin in Mexico, rights now encompassing all of North America

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Malvern (Pennsylvania) | April 18, 2022 9:55:06 PM IST
Biotechnology company Ocugen and Bharat Biotech (BBIL), on Monday, announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen's exclusive territory to include commercialization of COVAXIN in Mexico.

This gives Ocugen COVAXIN commercialization rights for all of North America, the company said in a press statement.

"We're excited to commercialize COVAXIN in Mexico, as authorities there have made conquering this pandemic a major priority. After meeting with Mexico's Secretary of Foreign Affairs, Marcelo Ebrard, in Delhi, we are encouraged by the role COVAXIN can play in Mexico's continuing efforts to defeat the COVID-19 pandemic. COVAXIN is currently under review by COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios) for emergency use among children between 2 and 18 years of age, and Ocugen is prepared to collaborate with the public health community to help their efforts. We also thank Bharat Biotech for helping make this opportunity a reality," said Dr Shankar Musunuri, Chairman of the Board, Chief Executive Officer and Co-founder of Ocugen, Inc.

COVAXIN can be an ideal vaccination option for Mexico at this stage of the pandemic. As a whole virion, inactivated vaccine, it elicits robust cellular immune memory to SARS-CoV-2 and Variants of Concern. It offers logistical advantages that could support vaccine access in hard-to-reach communities.

"We are delighted to announce our partnership with Ocugen for Mexico, along with the United States and Canada. COVAXIN is a safe and efficacious inactivated vaccine for all age groups as evident from its data from global introduction. We are fully supportive of team Ocugen in our endeavor to expedite technology transfer activities towards commercial-scale manufacturing of COVAXIN in North America," said Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech.

The license extension between Ocugen and Bharat Biotech with respect to commercialization in Mexico includes the same profit share structure as in the United States. (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE WORLD NEWS
Artificial Intelligence: The future is h...
China's COVID protests highlight need to...
As India assumes G20 presidency, PM Modi...
Australia, US vow to increase cooperatio...
Musk says fired Twitter counsel over con...
India voices concern over global food se...
More...
 
INDIA WORLD ASIA
MCD poll results: BJP leads over AAP in ...
Kerala govt appoints Mallika Sarabhai as...
India receiving G20 Presidency is a huge...
Delegation of Eastern Nagaland Peoples' ...
As Delhi witnesses 'too close to call' c...
Opposition leaders' meeting underway in ...
More...    
 
 Top Stories
Crucial meeting between Amit Shah a... 
LS: Rare display of unity by Congre... 
IND v BAN, 2nd ODI: Shreyas, Axar, ... 
Traders protest against two back to... 
'AAP only option to defeat corrupti... 
Pakistan: Police registers case aga... 
Dominating domestic cricket should ... 
Mahmudullah, Mehidy were brilliant ...